ORIC Pharmaceuticals, Inc.
ORIC
$5.26
-$0.52-9.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.40% | 13.06% | 14.05% | 14.09% | 19.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.91% | 33.60% | 44.11% | 12.90% | 42.09% |
| Operating Income | -25.91% | -33.60% | -44.11% | -12.90% | -42.09% |
| Income Before Tax | -28.16% | -35.67% | -39.31% | -4.45% | -35.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.16% | -35.67% | -39.31% | -4.45% | -35.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.16% | -35.67% | -39.31% | -4.45% | -35.89% |
| EBIT | -25.91% | -33.60% | -44.11% | -12.90% | -42.09% |
| EBITDA | -25.99% | -33.85% | -44.52% | -13.00% | -42.49% |
| EPS Basic | -4.24% | -10.39% | 9.59% | 30.06% | 5.10% |
| Normalized Basic EPS | -4.25% | -10.42% | 9.58% | 30.07% | 5.11% |
| EPS Diluted | -4.24% | -10.39% | 9.59% | 30.06% | 5.10% |
| Normalized Diluted EPS | -4.25% | -10.42% | 9.58% | 30.07% | 5.11% |
| Average Basic Shares Outstanding | 22.95% | 22.89% | 54.09% | 49.37% | 43.21% |
| Average Diluted Shares Outstanding | 22.95% | 22.89% | 54.09% | 49.37% | 43.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
